<p>IDH1-mutated relapsed or refractory AML: current challenges and future prospects</p>
نویسندگان
چکیده
منابع مشابه
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more ta...
متن کاملDown Syndrome: Current Status, Challenges and Future Perspectives
Down syndrome (DS) is a birth defect with huge medical and social costs, caused by trisomy of whole or part of chromosome 21. It is the most prevalent genetic disease worldwide and the common genetic cause of intellectual disabilities appearing in about 1 in 400-1500 newborns. Although the syndrome had been described thousands of years before, it was named after John Langdon Down who described ...
متن کاملTreatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin's lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment challenge. For both aggressive and indolent subtypes of NHL, there is no standard of care for salvage regimens, with prognosis after relapse remaining relatively poor. Nev...
متن کاملCurrent problems and future challenges
AS HISTORIANS review the advances of therapeutic science in the second half of the 20th century, one of the outstanding methodologic achievements will surely be the use of evidence from randomized trials to show the efficacy of new therapeutic agents. With this type of evidence, clinicians and patients can now be reasonably reassured, for the first time in medical history, that a new treatment ...
متن کاملAn intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML
We present a short case series of elderly patients with NK-AML and isolated NPM1 mutation who were treated with intensive chemotherapy, achieving significant CRs multiple times on reinduction, even with a single course.We hope to highlight the NPM1 as a molecular marker in elderly for consideration of aggressive treatment, even if abridged, as this subset may achieve a durable, good quality res...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood and Lymphatic Cancer: Targets and Therapy
سال: 2019
ISSN: 1179-9889
DOI: 10.2147/blctt.s177913